|
|
|
|
|
|
|
|
Cell-free or circulating tumour DNA (ctDNA) is tumour DNA circulating freely in the blood of a cancer patient.
~~~~~~~~~~~~~~~~~~
abstract
Purpose:
Chromosomal instability is a hallmark of ovarian cancer. Here, we
explore copy number alteration (CNA) profiling in cell-free DNA as a
potential biomarker to detect malignancy in patients presenting with an
adnexal mass.
Experimental design: We prospectively enrolled 68 patients with an
adnexal mass, of which 57 were diagnosed with invasive or borderline
carcinoma and 11 with benign disease. Cell-free DNA was extracted from
plasma and analyzed by low-coverage whole-genome sequencing.
Results: Patterns of chromosomal instability were detectable in
cell-free DNA using 44 healthy individuals as a reference. Profiles were
representative of those observed in matching tumor tissue and contained
CNAs enriched in 2 large datasets of high-grade serous ovarian cancer
(HGSOC). Quantitative measures of chromosomal instability, referred to
as genome-wide z-scores, were significantly higher in patients with
ovarian carcinoma than in healthy individuals or patients with benign
disease. Cell-free DNA testing improved malignancy detection (AUC 0.89)
over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC
0.81). AUC values of cell-free DNA testing even further increased for
HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a
theoretical threshold required for ovarian cancer screening, sensitivity
of cell-free DNA testing was 2 to 5-fold higher compared to CA-125 and
RMI testing.
Conclusions: This is the first study evaluating the potential of
cell-free DNA for the diagnosis of primary ovarian cancer using
chromosomal instability as a read-out. We present a promising method to
increase specificity of presurgical prediction of malignancy in patients
with adnexal masses.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.